Ken Griffin Hookipa Pharma Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.59 - $1.04 $5,133 - $9,048
-8,700 Reduced 34.25%
16,700 $9,000
Q1 2024

May 15, 2024
BUY
$0.61 - $0.83 $15,494 - $21,082
25,400 New
25,400 $18,000
Q2 2023

Aug 14, 2023
SELL
$0.71 - $1.97 $11,786 - $32,702
-16,600 Reduced 55.33%
13,400 $11,000
Q1 2023

May 15, 2023
BUY
$0.72 - $1.03 $6,264 - $8,961
8,700 Added 40.85%
30,000 $22,000
Q4 2022

Feb 14, 2023
BUY
$0.73 - $14.6 $7,373 - $147,460
10,100 Added 90.18%
21,300 $17,000
Q3 2022

Nov 14, 2022
SELL
$1.27 - $15.0 $17,653 - $208,500
-13,900 Reduced 55.38%
11,200 $15,000

Others Institutions Holding HOOK

# of Institutions
3
Shares Held
677K
Call Options Held
0
Put Options Held
0
View Full List

About HOOKIPA Pharma Inc.

HOOK Quotes by TradingView
  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $98.7M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email